In this issue of Interventional Cardiology Clinics, guest editor Dr. Luis Ortega Paz brings his considerable expertise to the topic of Antiplatelet and Anticoagulation Therapy in Cardiovascular and Pulmonary Embolism Transcatheter Interventions. Top experts in the field discuss regulation of platelet activation and coagulation; genetic determinants of P2Y12 inhibitors and clinical implications; switching P2Y12 receptor inhibiting therapies; high bleeding risk in patients undergoing coronary and structural heart interventions; and much more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. Foreword - p. xi 8. Preface - p. xiii 9. Regulation of Platelet Activation and Coagulation: Current Concepts, Novel Targets, and Therapies - p. 451 10. Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications - p. 469 11. High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions - p. 483 12. Antithrombotic Therapy in Patients with Chronic Coronary Syndromes - p. 493 13. Antithrombotic Therapy in Acute Coronary Syndrome - p. 507 14. Antithrombotic Therapy in Patients with Complex Percutaneous Coronary Intervention and Cardiogenic Shock - p. 517 15. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention - p. 527 16. Antithrombotic Therapy in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion - p. 543 17. Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions - p. 553 18. Anticoagulant Therapy in Patients Undergoing Acute Pulmonary Embolism Interventions - p. 561 19. Considerations in Antiplatelet Therapy in Women Undergoing Treatment of Acute Coronary Syndrome or Percutaneous Coronary Intervention - p. 577
In this issue of Interventional Cardiology Clinics, guest editor Dr. Luis Ortega Paz brings his considerable expertise to the topic of Antiplatelet and Anticoagulation Therapy in Cardiovascular and Pulmonary Embolism Transcatheter Interventions. Top experts in the field discuss regulation of platelet activation and coagulation; genetic determinants of P2Y12 inhibitors and clinical implications; switching P2Y12 receptor inhibiting therapies; high bleeding risk in patients undergoing coronary and structural heart interventions; and much more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. Foreword - p. xi 8. Preface - p. xiii 9. Regulation of Platelet Activation and Coagulation: Current Concepts, Novel Targets, and Therapies - p. 451 10. Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications - p. 469 11. High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions - p. 483 12. Antithrombotic Therapy in Patients with Chronic Coronary Syndromes - p. 493 13. Antithrombotic Therapy in Acute Coronary Syndrome - p. 507 14. Antithrombotic Therapy in Patients with Complex Percutaneous Coronary Intervention and Cardiogenic Shock - p. 517 15. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention - p. 527 16. Antithrombotic Therapy in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion - p. 543 17. Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions - p. 553 18. Anticoagulant Therapy in Patients Undergoing Acute Pulmonary Embolism Interventions - p. 561 19. Considerations in Antiplatelet Therapy in Women Undergoing Treatment of Acute Coronary Syndrome or Percutaneous Coronary Intervention - p. 577
